A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastasis|Breast Cancer
Interventions: DRUG: NKTR-102|DRUG: Eribulin|DRUG: Ixabepilone|DRUG: Vinorelbine|DRUG: Gemcitabine|DRUG: Paclitaxel|DRUG: Docetaxel|DRUG: Nab-paclitaxel
Sponsor: Nektar Therapeutics